Translationale Forschung

Dithranol in psoriasis and beyond

Dithranol in psoriasis and beyond

Studies on the therapeutic mechanisms of dithranol treatment in plaque-type psoriasis

In recent years, not much innovation has occurred for topical treatment options for patients with psoriasis. Although dithranol (anthralin) has been used as a topical treatment for plaque-type psoriasis for many years, its exact mechanism of action has remained largely unknown. Thus, the aim of this project is to unravel dithranol’s therapeutic mechanisms and to possibly uncover new targets for topical treatment of psoriasis. Our work so far revealed that dithranol exerts its anti-psoriatic effects by directly targeting keratinocytes and their crosstalk with neutrophils, as well as disrupting the IL-36 inflammatory loop.

Benezeder Theresa


I did my undergraduate studies in Biochemistry and Molecular Biomedicine at Karl-Franzens University and Technical University of Graz and I am now pursuing a PhD in Human Medicine in the international PhD program Molecular Fundamentals of Inflammation (DK-MOLIN) at the Medical University of Graz. In 2019, I joined Rachael Clark’s lab for a research stay at the Department of Dermatology, Harvard Medical School in Boston. Currently I am working in Prof. Wolf’s lab, my research focuses on therapeutic effects of dithranol, psoriasis and skin immunology.